Barclays PLC Increases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Barclays PLC lifted its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 70.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 155,179 shares of the biotechnology company’s stock after acquiring an additional 64,101 shares during the quarter. Barclays PLC’s holdings in Anavex Life Sciences were worth $882,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Orion Capital Management LLC increased its position in shares of Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 10,000 shares during the last quarter. Atria Investments Inc bought a new position in Anavex Life Sciences during the third quarter valued at about $76,000. BNP Paribas Financial Markets increased its holdings in Anavex Life Sciences by 97.0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after buying an additional 7,421 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Anavex Life Sciences by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 6,366 shares during the period. Finally, Erste Asset Management GmbH purchased a new position in Anavex Life Sciences in the third quarter valued at about $102,000. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Stock Down 0.8 %

Shares of NASDAQ:AVXL opened at $10.47 on Wednesday. The company has a 50-day moving average price of $9.55 and a two-hundred day moving average price of $7.06. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $14.44. The firm has a market capitalization of $888.02 million, a PE ratio of -20.94 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Analysts anticipate that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AVXL has been the subject of several research analyst reports. D. Boral Capital restated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research note on Monday. HC Wainwright raised their target price on Anavex Life Sciences from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, December 26th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.